TY - CHAP M1 - Book, Section TI - Small Cell Lung Cancer: Diagnosis, Treatment, and Natural History A1 - Dowell, Jonathan E. A1 - Drapkin, Benjamin J. A1 - Gerber, David E. A1 - Johnson, David H. A2 - Grippi, Michael A. A2 - Antin-Ozerkis, Danielle E. A2 - Dela Cruz, Charles S. A2 - Kotloff, Robert M. A2 - Kotton, Camille Nelson A2 - Pack, Allan I. PY - 2023 T2 - Fishman’s Pulmonary Diseases and Disorders, 6e AB - Small-cell lung cancer (SCLC) is, in many ways, a unique tumor. Untreated, it is a highly virulent malignancy, with a life expectancy best measured in weeks. Conversely, it displays exquisite chemosensitivity, resulting in partial or complete responses in the majority of cases. For the first time in more than 30 years, the standard of care for advanced SCLC has changed with the addition of immune checkpoint inhibitor therapy to standard chemotherapy. Unfortunately, even with this advance, durable tumor responses are rare, and as a result, more than 95% of SCLC patients die from their disease. This chapter reviews the biology, epidemiology, diagnosis, clinical presentation, staging, and current management of this difficult disease. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1195013481 ER -